Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
TMC125 Demonstrates Significant Efficacy in Treatment-Experienced Patients with NNRTI Resistance in Phase III trials Jul 6, 2007 |
9.6 KB |
|
|
CORK, Ireland, 6th July 2007 - TMC125 (etravirine, ETR), Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, according to the 24-week primary endpoint analysis from two ongoing, phase III studies published in the 7 July, 2007, is... |
|||
|
New PREZISTA® Phase III Study meets primary objective of non-inferiority and secondary objective of superiority in virologic response vs. KALETRA® in treatment-experienced HIV patients Jul 6, 2007 |
12.8 KB |
|
|
CORK, Ireland, 6th July 2007 - Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults* taking Prezista® (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral load of less than 400 copies/mL at week 48... |
|||
|
INVEGA™ Receives Marketing Authorization In European Union For Treatment Of Schizophrenia Jun 28, 2007 |
14.2 KB |
|
|
TITUSVILLE, N.J., June 28 /PRNewswire/ -- The European Commission granted marketing authorization for INVEGA™ (paliperidone prolonged release tablets), an atypical antipsychotic medication for the treatment of schizophrenia. This once-daily medication is specifically designed to deliver paliperidone - the acti... |
|||
|
World Council of Optometry Awards ACUVUE(R) ADVANCE(TM), ACUVUE(R) OASYS(TM) Brands With Global Seal of Acceptance for UV Absorbing Contact Lenses Jun 28, 2007 |
11.7 KB |
|
|
BOSTON, Jun 28, 2007 (PR Newswire Europe via COMTEX News Network) -- Contact Lenses Meet Highest Standard for Contact Lens UV Protection Johnson & Johnson Vision Care, Inc., today announced that its ACUVUE(R) ADVANCE(TM) with HYDRACLEAR(TM), ACUVUE(R) ADVANCE(TM) for ASTIGMATISM, and ACUVUE(R) OASYS(TM) with HYDRACLEAR(TM) PLUS Brand Contact Le... |
|||
|
FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania Jun 21, 2007 |
9.9 KB |
|
|
TITUSVILLE, N.J., June 21, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced it has received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding two supplemental New Drug Applications (sNDA) for RISPERDAL(R) (risperidone), filed on Dec. 21, 200... |
|||
|
Johnson & Johnson Invites Nominations for the 2008 Dr. Paul Janssen Award for Biomedical Research Jun 14, 2007 |
11.4 KB |
|
|
NEW BRUNSWICK, N.J., June 14, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson today announced that it is accepting nominations for The 2008 Dr. Paul Janssen Award for Biomedical Research. Nominations will be accepted on-line at http://www.pauljanssenaward.com until December 1, 2007, and the winner will be announced in September 2008.... |
|||
|
Cordis Corporation Resolves Corporate Warning Letter Jun 14, 2007 |
6.5 KB |
|
|
MIAMI LAKES, Fla., June 14, 2007 /PRNewswire via COMTEX News Network/ -- Cordis Corporation today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that all items outlined in the company's warning letter have been resolved. "We are pleased that the FDA warning letter is now resolved," said Rick Anderso... |
|||
|
William D. Perez of Wm. Wrigley Jr. Company Appointed to Johnson & Johnson Board of Directors Jun 12, 2007 |
6.5 KB |
|
|
NEW BRUNSWICK, N.J., June 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has unanimously appointed William D. Perez, President and Chief Executive Officer of the Wm. Wrigley Jr. Company, as a Director of Johnson & Johnson, the world's most broadly based health car... |
|||
|
New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty Procedures Jun 7, 2007 |
7.7 KB |
|
|
BALTIMORE, June 7, 2007 /PRNewswire via COMTEX News Network/ -- Today at the 61st Annual Meeting of the Society for Vascular Surgery, Cordis Endovascular, division of Cordis Corporation, announced the worldwide launch of the Cordis AVIATOR(TM) Plus Balloon Dilatation Catheter for use in angioplasty procedures for patients with carotid and or renal ... |
|||
|
Johnson & Johnson Highlights Growth Strategies for Pharmaceutical and Consumer Businesses Jun 7, 2007 |
13.2 KB |
|
|
NEW BRUNSWICK, N.J., June 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson highlighted its Pharmaceutical and Consumer businesses at a meeting with financial analysts today, describing its broadly based health care business as strong and poised for continued growth in the coming years. Senior leaders from the company outl... |
|||
|
New Drug Application Submitted for Investigational Antibiotic Doripenem Jun 6, 2007 |
11.1 KB |
|
|
RARITAN, N.J., June 6, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pne... |
|||
|
VISTAKON(R) Launches Electronic Contact Lens Reminder Service to Help Improve Contact Lens Compliance Jun 6, 2007 |
7.3 KB |
|
|
JACKSONVILLE, Fla., June 6, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Contact lens wearers no longer have to worry about forgetting to replace their lenses as recommended by their eye care doctor. Today, VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc. and maker of ACUVUE(R) Brand Contact Lenses, announced the national laun... |
|||
|
New Study Suggests Better Patient Outcomes with CYPHER(R) Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings Jun 4, 2007 |
9.7 KB |
|
|
MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark Heart Registry found that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent to open a clogged artery were less likely to need another procedure at that same lesion site (a clinical event called target lesion revasc... |
|||
|
Johnson & Johnson To Host Pharmaceutical and Consumer Business Review May 29, 2007 |
6.8 KB |
|
|
NEW BRUNSWICK, N.J., May 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an all-day review of its Pharmaceutical and Consumer businesses for financial analysts beginning at 8:30 a.m. (EDT) on Thursday, June 7, 2007, at the Hyatt Regency Hotel in New Brunswick, N.J. Colleen Goggins, Worldwide Chairman, Cons... |
|||
|
CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease May 22, 2007 |
10.6 KB |
|
|
BARCELONA, Spain, May 22, 2007 /PRNewswire via COMTEX News Network/ -- A three-year follow-up subset analysis presented today as a late-breaking clinical trial at EuroPCR 2007 showed that the CYPHER(R) Sirolimus-eluting Coronary Stent had results comparable to coronary artery bypass grafting (CABG or bypass surgery) and better outcomes than bare me... |
|||
|
Johnson & Johnson to Participate in Bank of America 2007 Health Care Conference May 21, 2007 |
6.4 KB |
|
|
NEW BRUNSWICK, N.J., May 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the Bank of America 2007 Health Care Conference on Thursday, May 31st, at the Four Seasons Hotel in Las Vegas, Nev. Nick Valeriani, Worldwide Chairman, Medical Devices & Diagnostics for Johnson & Johnson, will represent the comp... |
|||
|
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole May 18, 2007 |
10.5 KB |
|
|
RARITAN, N.J., May 18, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced today that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for ceftobiprole, an investigational antibiotic, for the treatment of complicated ski... |
|||
|
Johnson & Johnson to Participate in Citigroup's Global Healthcare Conference May 16, 2007 |
6.4 KB |
|
|
NEW BRUNSWICK, N.J., May 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in Citigroup's Global Healthcare Conference on Wednesday, May 23rd at the Hilton Hotel in New York. David Norton, Company Group Chairman, Worldwide Commercial and Operations, CNS/Internal Medicine Franchise, will represent the Comp... |
|||
|
Cordis To Host Analyst Meeting At EuroPCR 2007 May 16, 2007 |
6.7 KB |
|
|
NEW BRUNSWICK, N.J., May 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Cordis, a Johnson & Johnson company, will host a meeting for financial analysts at 14:00 Central European Time (8:00 a.m. EDT) on May 23rd at the EuroPCR 2007 Conference in Barcelona, Spain. Rick Anderson, Company Group Chairman, and Dr. Campbell Rogers, Chief T... |
|||
|
Southern District Court of New York Rules Patent for ACIPHEX® Enforceable May 11, 2007 |
8.2 KB |
|
|
Raritan, N.J. (May 11, 2007) – PriCara™, Unit of Ortho-McNeil, Inc., announced today that the Southern District Court of New York ruled that the patent for ACIPHEX® (rabeprazole sodium 20 mg tablets) is enforceable. PriCara and Eisai Inc. co-promote ACIPHEX® in the United States. In an earlier ruling, the Court confirmed th... |
|||
= add release to Briefcase
